License and Asset Acquisitions - Additional Information (Details) - USD ($)				1 Months Ended			12 Months Ended
	May 11, 2020	Sep. 21, 2018	Oct. 02, 2017	May 31, 2019	Jun. 30, 2018	Oct. 31, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
In process research and development							$ 75,000	$ 23,380,000	$ 3,600,000
Seralutinib
Business Acquisition [Line Items]
In process research and development							0	5,000,000	0
GB004
Business Acquisition [Line Items]
In process research and development							0	15,000,000	0
GB1275
Business Acquisition [Line Items]
In process research and development							0	0	$ 1,000,000
Pulmokine, Inc. | License Agreement | Seralutinib
Business Acquisition [Line Items]
Product license term			10 years
Upfront payment						$ 5,500,000
Milestones accrued							0	5,000,000
Pulmokine, Inc. | License Agreement | Seralutinib | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable			$ 58,000,000
Commercial milestone payments, payable			45,000,000
Sales milestone payments, payable			$ 190,000,000
Aadi Biosciences, Inc. | License Agreement | GB004
Business Acquisition [Line Items]
Upfront payment	$ 15,000,000
Milestones accrued							0	0
Upfront payment, purchase consideration paid					$ 20,000,000
Participation right (in percentage)					20.00%
Aadi Biosciences, Inc. | License Agreement | GB004 | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable	40,000,000
Sales milestone payments, payable	$ 50,000,000
Adhaere Pharmaceuticals, Inc. | GB1275
Business Acquisition [Line Items]
Milestones accrued							$ 0	$ 0
Upfront payment, purchase consideration paid		$ 7,500,000
In process research and development		7,500,000
Milestones payment				$ 1,000,000
Adhaere Pharmaceuticals, Inc. | GB1275 | Maximum
Business Acquisition [Line Items]
Regulatory, development and sales milestone payments payable		$ 62,000,000